Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial

IMPORTANCE: Drug development for metastatic castration-resistant prostate cancer has been limited by a lack of clinically relevant trial end points short of overall survival (OS). Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: Rathkopf, Dana E., Beer, Tomasz M., Loriot, Yohann, Higano, Celestia S., Armstrong, Andrew J., Sternberg, Cora N., de Bono, Johann S., Tombal, Bertrand, Parli, Teresa, Bhattacharya, Suman, Phung, De, Krivoshik, Andrew, Scher, Howard I., Morris, Michael J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2018
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885186/
https://ncbi.nlm.nih.gov/pubmed/29522174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5808
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge